Table 2.
Treatment effects for all contrast in terms of pain (pain VAS) along with 95% credible interval and probability that treatment is better than the comparator
| Intervention |
Comparator |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo | MTX | aTNF | Tocilizumab | aTNF + MTX | Abatacept + MTX | Anakinra + MTX | Tocilizumab + MTX | ||
| Placebo |
Estimate |
0 |
14.71 |
20.17 |
31.28 |
32.53 |
37.63 |
22.00 |
30.71 |
| 95% CrI |
|
(-3.85, 33.43) |
(12.33, 29.73) |
(18.69, 45.21) |
(13.46, 52.09) |
(6.71, 67.22) |
(0.86, 42.52) |
(15.14, 46.97) |
|
| P(better) |
|
5% |
<1% |
<1% |
<1% |
1% |
2% |
<1% |
|
| MTX |
Estimate |
-14.71 |
0 |
5.42 |
16.55 |
17.85 |
22.98 |
7.29 |
15.97 |
| 95% CrI |
(-33.43, 3.85) |
|
(-10.37, 24.07) |
(3.81, 31.31) |
(13.02, 23.08) |
(-1.54, 47.31) |
(-2.54, 16.69) |
(6.26, 26.34) |
|
| P(better) |
95% |
|
22% |
1% |
<1% |
3% |
5% |
<1% |
|
| aTNF |
Estimate |
-20.17 |
-5.42 |
0 |
11.09 |
12.40 |
17.27 |
1.84 |
10.60 |
| 95% CrI |
(-29.73, -12.33) |
(-24.07, 10.37) |
|
(0.09, 21.3) |
(-6.63, 29.01) |
(-13.17, 45.84) |
(-19.57, 19.71) |
(-4.53, 23.59) |
|
| P(better) |
>99% |
78% |
|
2% |
7% |
12% |
40% |
6% |
|
| Tocilizumab |
Estimate |
-31.28 |
-16.55 |
-11.09 |
0 |
1.30 |
6.23 |
-9.29 |
-0.56 |
| 95% CrI |
(-45.21, -18.69) |
(-31.31, -3.81) |
(-21.3, -0.09) |
|
(-13.98, 15.15) |
(-21.98, 33.48) |
(-27.22, 6.19) |
(-10.64, 8.41) |
|
| P(better) |
>99% |
99% |
98% |
|
41% |
33% |
91% |
56% |
|
| aTNF + MTX |
Estimate |
-32.53 |
-17.85 |
-12.40 |
-1.30 |
0 |
5.06 |
-10.60 |
-1.85 |
| 95% CrI |
(-52.09, -13.46) |
(-23.08, -13.02) |
(-29.01, 6.63) |
(-15.15, 13.98) |
|
(-19.92, 29.83) |
(-21.84, -0.05) |
(-12.93, 9.48) |
|
| P(better) |
>99% |
>99% |
93% |
59% |
|
35% |
98% |
65% |
|
| Abatacept + MTX |
Estimate |
-37.63 |
-22.98 |
-17.27 |
-6.23 |
-5.06 |
0 |
-15.61 |
-6.93 |
| 95% CrI |
(-67.22, -6.71) |
(-47.31, 1.54) |
(-45.84, 13.17) |
(-33.48, 21.98) |
(-29.83, 19.92) |
|
(-42.08, 10.48) |
(-33.04, 19.51) |
|
| P(better) |
99% |
97% |
88% |
67% |
65% |
|
89% |
70% |
|
| Anakinra + MTX |
Estimate |
-22.00 |
-7.29 |
-1.84 |
9.29 |
10.60 |
15.61 |
0 |
8.73 |
| 95% CrI |
(-42.52, -0.86) |
(-16.69, 2.54) |
(-19.71, 19.57) |
(-6.19, 27.22) |
(0.05, 21.84) |
(-10.48, 42.08) |
|
(-4.56, 23.05) |
|
| P(better) |
98% |
95% |
60% |
9% |
2% |
11% |
|
7% |
|
| Tocilizumab + MTX | Estimate |
-30.71 |
-15.97 |
-10.60 |
0.56 |
1.85 |
6.93 |
-8.73 |
0 |
| 95% CrI |
(-46.97, -15.14) |
(-26.34, -6.26) |
(-23.59, 4.53) |
(-8.41, 10.64) |
(-9.48, 12.93) |
(-19.51, 33.04) |
(-23.05, 4.56) |
|
|
| P(better) | >99% | >99% | 94% | 44% | 35% | 30% | 93% | ||
P(better) = Probability that treatment (in row) is showing greater efficacy than comparator (in column); CrI = credible interval; aTNF = Anti-tumor necrosis factor.